About US
Contact us
-
UK CMA accuses Merck of breaking competition law with discount schemeThe UK Competition and Markets Authority (CMA) has accused US pharmaceutical company Merck Sharp & Dohme(MSD) of operating an anti-competitive discount scheme for its medicine Remicade. Remicade2017/7/14
-
AC Immune and Essex to develop biological treatment for neurodegenerative diseasesAC Immune and Essex Bio-Technology have signed a research collaboration agreement to conduct a pre-clinical study and clinical codevelopment of a novel biological therapeutic to treat neurodegenerativ2017/7/13
-
Cancer Research UK funded scientists to test Zika virus on brain tumoursScientists funded by Cancer Research UK will investigate the effectiveness of the Zika virus in destroying brain tumour cells, which could lead to new treatments for cancer. Under the initiative, Dr2017/7/11
-
J&J completes Actelion acquisition for $30bnJohnson & Johnson (J&J) has completed the acquisition of Actelion Pharmaceuticals for approximately $30bn in an all-cash transaction through its Swiss subsidiary Janssen Holding. The European2017/7/8
-
Integral Molecular begins immuno-oncology therapeutic targets discoveryUS-based research-driven biotechnology company Integral Molecular has begun a therapeutic target discovery programme in immuno-oncology by utilising its membrane proteome array technology to identify2017/7/7
-
Boehringer opens biopharmaceutical manufacturing facility in ChinaGermany’s Boehringer Ingelheim has officially opened its commercial production site for biopharmaceuticals in Zhang Jiang Hi-tech Park in Shanghai, China. The facilitycarries a first-phase investment2017/7/6
-
Endo caves to FDA pressure, will pull Opana ER from the marketUnder pressure from the FDA, Endo has decided to pull from the market its opioid painkiller Opana ER, a drug that generated nearly $160 million in sales last year. The Dublin-based drugmakersaidthat2017/6/28
-
Forget Sanofi's Zika shot. A new measure would limit pricing on all DOD-funded medicationThe controversy over Sanofi's eventual pricing for an in-development Zika vaccine might just spawn pricing constraints for all treatments developed with the help of Defense Department funding. Under2017/6/25
-
Is 2017 set to be the year we see a CAR-T therapy approved? Let’s find out from the leaders in the fieldUsing your body’s own cells, engineering them to target tumors and cure cancer sounds like something from a Sci-Fi movie but it’s not, it’s happening right now!CAR-TandTCRtherapies have taken theimm2017/6/24
-
Trial deaths frustrate Merck's bid to pair Keytruda with Celgene's myeloma starsAfter reviewing deaths in two Keytruda trials, the FDA put both Merck studies on clinical hold and stopped Keytruda dosing in a third, thwarting Merck's hopes for combining Keytruda with Celgene's big2017/6/23